Axovant has licensed two gene therapies from the University of Massachusetts Medical School (UMMS). The deal accelerates Axovant’s evolution into a gene therapy specialist by giving it control of two ...

After just 10 months at the helm, Axovant’s CEO David Hung, MD, resigned Monday to “pursue other opportunities.” In addition, Axovant’s president and COO Marion McCourt and three board members also ...

SAN FRANCISCO—J.P. Morgan week one year ago wasn’t Axovant’s finest hour. But since Pavan Cheruvu—formerly Roivant’s chief people officer—took Axovant’s helm in February 2018, the company has been ...

The legacy of Axovant Gene Therapies (NASDAQ: AXGT) is one of disappointment. The business soared to a market capitalization of $2.4 billion in mid-2017 on high hopes for a promising drug pipeline, ...

Shares of Axovant Gene Therapies (NASDAQ: AXGT) fell more than 16% today after the company announced the pricing of a stock offering. The gene therapy developer will sell up to 30.7 million shares of ...

Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced the first patients screened in MINDSET, a confirmatory ...

One stock that might be an intriguing choice for investors right now is Axovant Gene Therapies Ltd. AXGT. This is because this security in the Medical - Biomedical and Genetics space is seeing solid ...

BASEL, Switzerland, April 10, 2017 /PRNewswire/ -- Axovant Sciences (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced that David ...

Axovant Gene Therapies Ltd. AXGT was a big mover last session, as the company saw its shares rise nearly 12% on the day. The move came on solid volume too with far more shares changing hands than in a ...

NEW YORK and BASEL, Switzerland, Jan. 13, 2020 (GLOBE NEWSWIRE) -- Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company developing innovative gene therapies for neurological diseases, ...

Axovant Sciences Ltd. (NASDAQ: AXON) shares saw a handy gain on Monday after the company announced that it has licensed exclusive global rights to an investigational silence-and-replace gene therapy ...

At Insider Monkey, we pore over the filings of nearly 750 top investment firms every quarter, a process we have now completed for the latest reporting period. The data we’ve gathered as a result gives ...